ELTX (Elicio Therapeutics) Long-Term Debt: $9.48 Mil (As of Mar. 2026)


ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $3.18
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Long-Term Debt?

Elicio Therapeutics ELTX -9.15% 32 Long-Term Debt is $9.48 Mil as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Elicio Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $9.48 Mil.

Elicio Therapeutics's quarterly Long-Term Debt declined from Sep. 2025 ($9.72 Mil) to Dec. 2025 ($9.41 Mil) but then increased from Dec. 2025 ($9.41 Mil) to Mar. 2026 ($9.48 Mil).

Elicio Therapeutics's annual Long-Term Debt increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($20.03 Mil) but then declined from Dec. 2024 ($20.03 Mil) to Dec. 2025 ($9.41 Mil).

Elicio Therapeutics  (NAS:ELTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Elicio Therapeutics Long-Term Debt Related Terms

Elicio Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Long-Term Debt Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 20.03 9.41

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 9.34 9.72 9.41 9.48
ELTX
32GF Score
Elicio Therapeutics Inc ELTX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $9.48 Mil mean?
Elicio Therapeutics (ELTX) has a Long-Term Debt of $9.48 Mil as of Mar. 2026.
Is Elicio Therapeutics' Long-Term Debt too high?
Elicio Therapeutics' current Long-Term Debt is $9.48 Mil. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Long-Term Debt compare to GOSS and GANX?
Elicio Therapeutics' Long-Term Debt of $9.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Elicio Therapeutics's current Long-Term Debt is $9.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Long-Term Debt of $9.48 Mil. The current Long-Term Debt is $9.48 Mil. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Long-Term Debt is $9.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price